May 7, 2020
Tony Hagen
The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.
May 6, 2020
Deana Ferreri
Although the totality of the evidence is reassuring, the jury is still out on nonmedical switching to biosimilars, according to new study results.
April 11, 2020
The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.
April 7, 2020
Deana Ferreri, PhD
In inflammatory bowel diseases (IBD), biosimilars have been available for roughly 5 years, but more evidence may be necessary to persuade medical community to increase usage, according to a study.
March 31, 2020
Canadian provinces encounter opposition in their move to implement forced switching of patients from reference products to biosimilars.
March 6, 2020
Skylar Jeremias
Only 24% of providers were comfortable with prescribing biosimilars for patients with inflammatory bowel disease (IBD).
February 25, 2020
The study compared the stool samples of patients with ulcerative colitis (UC) with patients with familial adenomatous polyposis. Both groups may have colectomies, but only the patients with UC have inflammation that may return even after surgery.
February 21, 2020
The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.
February 18, 2020
Because of the high cost of biologics, the authors recognized a need to provide access to evidence-based information on biosimilars for healthcare providers working with patients with inflammatory bowel disease.
January 22, 2020
The Center for Biosimilars Staff
Health New England says it achieved 93% utilization by requiring prior authorization.
